Akari医疗公共 AKTX 深 沪
等待开盘 09-08 09:30:00 美东时间
0.8187
+0.089
+12.15%
华盛通- 最 高0.8188
- 今 开0.6998
- 成交量 7.10万股
- 最 低 0.6901
- 昨 收 0.73
- 总市值 2634.28万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 0.5714
- 委 比 -52.43%
- 总股本 3217.64万
- 历史最高 2380.00
- 量 比 0.38
- 振 幅 17.63%
- 历史最低 0.5714
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Akari Therapeutics的CEO Abizer Gaslightwala将在2025年9月8日至10日在纽约举行的H.C. Wainwright全球投资会议上发表演讲，并在会议期间与投资者进行一对一会谈。公司专注于开发下一代载荷抗体药物偶联物（ADCs），其领先候选药物AKTX-101使用新型PH1载荷，通过干扰癌细胞的RNA剪接机制诱导癌细胞死亡并激活免疫反应，展现出显著的临床前活性。公司正推进该药物的开发，并探索其与免疫检查点抑制剂的协同作用。演讲视频网络直播将可在公司网站上观看。
09-05 10:45
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Akari Therapeutics will participate in the Virtual Investor Closing Bell Series on September 4, 2025, at 4:00 PM ET. Abizer Gaslightwala, CEO, will discuss the company's innovative payload platform for next-generation ADCs targeting various cancer tumor types. Live webcast and replay available on akaritx.com. Akari's PH1 payload disrupts RNA splicing, showing robust anti-tumor activity and immune activation in preclinical studies, with AKTX-101 d...
09-03 12:30
Akari Therapeutics Cancels Peak Bio Note and Loan
Akari Therapeutics ( ($AKTX) ) has issued an announcement. Akari Therapeutics h...
08-22 05:30
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:00 PM ET. CEO Abizer Gaslightwala will discuss the company's novel ADCs, including its PH1 payload, which targets RNA splicing in cancer cells. Akari's lead candidate, AKTX-101, has shown promising preclinical results and potential synergy with checkpoint inhibitors. The presentation is open to registered attendees.
08-14 13:15
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
Kymera Therapeutics, a clinical-stage biotech company, will report its second-quarter 2025 financial results on August 11 and host a video conference call and webcast at 8:30 a.m. ET. The company specializes in developing oral small molecule degrader medicines for immunological diseases using targeted protein degradation technology. Interested parties can register via the provided links or visit the Investor section on the company’s website.
08-04 11:00
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
Akari Therapeutics highlights PH1, a spliceosome modulator that kills cancer cells and activates the immune system. Its ADC pipeline uses PH1 against Trop2 and an undisclosed target. Upcoming preclinical data on PH1's impact against a key oncogenic driver is expected by year-end.
07-23 12:55
Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Akari Therapeutics的CEO Abizer Gaslightwala参加了Virtual Investor夏季投资者会议，分享了他对于公司ADC药物开发的热情和愿景。Akari专注于创新ADC药物，其PH1ayload通过干扰RNA剪接机制，展现出比传统ADC更强的抗肿瘤活性。主力产品AKTX-101在临床前研究中表现出显著疗效，并可与免疫检查点抑制剂协同作用。公司正在推进PH1ayload的验证性数据收集以推动产品开发。如需更多信息，请访问其官网或联系投资者关系团队。
07-22 12:45
美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5
Maxim Group analyst Jason McCarthy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $5.
07-19 00:28
